OPHTHALMIC USE OF AGENTS WHICH INHIBIT CONNECTIVE TISSUE GROWTH FACTOR BINDING AND SIGNALLING VIA THE TRKA/P75NTR RECEPTOR COMPLEX

摘要

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one agent that inhibits binding and/or signaling of connective tissue growth factor (CTGF) via the TrkA/p75SUPNTR/SUP receptor complex. In a preferred embodiment, the present invention relates to the use of the tyrosine kinase inhibitor K-252a in the treatment of CTGF-mediated ocular disorders like glaucomas.